ArticleFrontiers in neurology
Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06867991 (Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-NMDA receptor encephalitis (NMDARE) is the most common autoimmune encephalitis, involving an immune response against NMDA receptors on neurons. Despite standard immunotherapy, approximately 30% of critically ill patients require long-term intensive care. Current management strategies are mainly based on retrospective studies and expert opinions, with limited high-quality evidence. This study aims to evaluate the efficacy and safety of B-cell depleting agents followed by daratumumab as a second-line treatment for severe autoimmune encephalitis (AE) with NMDARE as the primary target population. Objective: To describe the study protocol for the RADIA study. Study design: This multicenter, open-label, randomized controlled trial is conducted across 58 tertiary hospitals in China. Eligible participants are patients with severe AE especially NMDARE (mRS ≥ 3 points and neuropsychiatric manifestations inadequate to symptomatic treatment) post first-line immunotherapy. A total of 200 patients will be randomized at a 2:2:1 ratio into three groups. 80 patients will receive B-cell depleting agent (anti-CD20 mAb ofatumumab) followed by anti-CD38 mAb daratumumab, 80 patients will receive B-cell depleting agent ofatumumab alone, and 40 receive repeated IVIG or plasmapheresis. Main outcome measures: The primary endpoint is the proportion of patients with an mRS score ≤ 2, assessed at 16 weeks after treatment initiation. The secondary outcomes include scores on the Clinical Assessment Scale for Autoimmune Encephalitis (CASE), neurocognitive function, antibody status, ICU stay, and hospitalization duration up to 48 weeks. Adverse events will be monitored continuously. Conclusion: This trial aims to provide robust data on the efficacy of B cell depleting agents followed by daratumumab in patients with severe AE, with a primary focus on the NMDARE subgroup. This combined regimen may provide a new treatment option for NMDARE. Clinical trial registration: https://clinicaltrials.gov/study/NCT06867991, identifier (NCT06867991).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.